Innate Pharma (XPAR:IPH) Other Current Liabilities : €7.82 Mil (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Innate Pharma Other Current Liabilities?

Innate Pharma's other current liabilities for the quarter that ended in Dec. 2023 was €7.82 Mil.

Innate Pharma's quarterly other current liabilities declined from Dec. 2022 (€11.77 Mil) to Jun. 2023 (€8.29 Mil) and declined from Jun. 2023 (€8.29 Mil) to Dec. 2023 (€7.82 Mil).

Innate Pharma's annual other current liabilities increased from Dec. 2021 (€8.07 Mil) to Dec. 2022 (€11.77 Mil) but then declined from Dec. 2022 (€11.77 Mil) to Dec. 2023 (€7.82 Mil).

Innate Pharma Other Current Liabilities Historical Data

The historical data trend for Innate Pharma's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Other Current Liabilities Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Liabilities

Get a 7-Day Free Trial

Innate Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Current Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Innate Pharma Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Innate Pharma Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma (XPAR:IPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (XPAR:IPH) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

IPHYF:USA IPHA:USA 0EVI:UK IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Innate Pharma (XPAR:IPH) Headlines

No Headlines